Patients with TNBC have a poorer prognosis than those who present with HR-positive or HER2-positive disease. This CME/CE-approved discussion on metastatic TNBC with Sara Tolaney, MD, MPH and Sara Hurvitz, MD will evaluate personalized care plans, genetic risk evaluation, and novel therapies.

This online strategy session features a discussion between Stephanie Jackson, MSN, RN, AOCNS, BMTCN and Leslie Smith, RN, APRN-CNS, AOCNS on CAR T-cell therapy in patients with B-cell malignancies such as T-cell workflow, efficacy and safety data, as well as adverse event management.

This case-based discussion on metastatic gastric cancer features Jaffer A. Ajani, MD and Allyson J. Ocean, MD as they examine individualized treatment selection, novel therapies, and adverse event management. Download the clinician's resource guide today!

In this case-based activity, Alicia K. Morgans, MD, MPH and Tanya Dorff, MD discuss predictive and prognostic markers, recent findings, novel treatments, and supportive care plans for patients with castration-resistant prostate cancer.

In this online activity, Craig H. Moskowitz, MD and Kami Maddocks, MD discuss factors that increase risk for cHL treatment failure, emerging data on the treatment of newly diagnosed and relapsed/refractory cHL, and assess strategies to manage toxicities associated with therapy.

This case-based online activity features a discussion between leading clinical investigators, Ramez Eskander, MD and Bradley Monk, MD, FACS, FACOG, as they explore the management of advanced cervical cancer with checkpoint inhibitor therapy.